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iSPECIAL ARTICLE1835Standardized Cardiovascular Data for Clinical Research, Registries, and Patient CareH. Vernon Anderson, William S. Weintraub, Martha J. Radford, Mark S. Kremers, Matthew T. Roe,
Richard E. Shaw, Dana M. Pinchotti, James E. Tcheng
Clinical research studies are usually organized as separate and distinct efforts conducted locally
at independent sites. As a result, little attention has been focused on standardization of data
to allow for easy exchange between groups. As part of the National Cardiovascular Research
Infrastructure (NCRI), a Data Standard Workgroup was established to create, identify, and
establish clinical definitions for a base set of standardized cardiovascular elements to serve as a
foundation of a national cardiovascular clinical and research infrastructure. This paper
provides the background and reports on the initial results of the efforts of NCRI Data
Standard Workgroup whom have assembled a set of 353 cardiovascular data elements with
definitions. This work builds on previous efforts to establish a base cardiovascular vocabulary
for electronic health records. Once fully implemented, these elements will be useful in
facilitating clinical research, reporting, and regulatory compliance.CLINICAL RESEARCH INTERVENTIONAL CARDIOLOGY1847Bleeding Risk and Bivalirudin UseSeshu C. Rao, Adnan K. Chhatriwalla, Kevin F. Kennedy, Carole J. Decker, Elizabeth Gialde,
John A. Spertus, Steven P. Marso
Although bivalirudin use during percutaneous coronary intervention (PCI) has been shown to
reduce bleeding complications a paradox exists in which patients at highest risk for bleeding
are least likely to receive bivalirudin. Rao and colleagues investigate whether estimation of
bleeding risks pre-procedure, impacts utilization of bivalirudin during PCI. Bivalirudin use
was compared in 6,491 PCI procedures (in patients with low, moderate, and high risk of
bleeding), pre- and post-introduction of bleeding risk estimates. Overall bivalirudin use
increased in the post-implementation period (26.9% vs. 34.2%, p  0.001). Use increased in
igh- and intermediate-risk patients and decreased in the low-risk patients. Bleeding
omplications decreased in intermediate- (3.4% to 1.8%, p  0.009) and high-risk (6.9% to
.7%, p  0.005) and remained unchanged in low-risk patients. The authors concluded that
here was an increase in bivalirudin use and lower incidence of bleeding after incorporation of
ndividual bleeding risk estimate into clinical practice.(continued on page A-24)
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Alexander Parkhomenko, Michal Tendera, Petr Widimsky, C. Michael Gibson
The original ATLAS-ACS 2–TIMI 51 study evaluated the effects of adding rivaroxaban, a
novel Xa inhibitor in patients presenting with acute coronary syndrome (ACS). The results
revealed reduced cardiovascular events across the spectrum of ACS. In this paper, Mega and
colleagues report on the effect of this drug on a pre-specified subgroup of ST-segment
elevation myocardial infarction (STEMI) patients. A total of 7,817 STEMI patients were
randomized to twice daily rivaroxaban 2.5 mg, rivaroxaban 5 mg, or placebo. Among STEMI
patients rivaroxaban reduced the primary efficacy endpoint of cardiovascular death, myocardial
infarction, or stroke as compared with placebo (intention-to-treat: 8.4% vs. 10.6%, hazard
ratio [HR]: 0.81, 95% confidence interval [CI]: 0.67 to 0.87, p  0.019; modified intention-
to-treat: 8.3% vs. 9.7%, HR: 0.85, 95%: CI: 0.70 to 1.03, p  0.09). Only rivaroxaban 2.5
mg reduced cardiovascular death. Rivaroxaban versus placebo increased non-coronary artery
bypass grafting TIMI major bleeding (2.2% vs. 0.6%, p  0.01) and intracranial hemorrhage
(0.6% vs. 0.1%, p  0.015) without increase in fatal bleeding (0.2% vs. 0.1%, p  0.51). In
patients with recent STEMI, rivaroxaban reduced cardiovascular events but increased the rate
of major bleeding but no increase in fatal bleeding.CORONARY ARTERY DISEASE1860Ischemia and Outcome With LV DysfunctionJulio A. Panza, Thomas A. Holly, Federico M. Asch, Lilin She, Patricia A. Pellikka, Eric J. Velazquez,
Kerry L. Lee, Salvador Borges-Neto, Pedro S. Farsky, Robert H. Jones, Daniel S. Berman, Robert O. Bonow
The clinical significance of stress-induced ischemia in patients with coronary artery disease
(CAD) and moderate to severe reduced left ventricular (LV) ejection fraction (EF) is largely
unknown. The investigators evaluate the hypothesis that ischemia during stress test identifies
those patients with CAD and LV dysfunction who derive greatest benefit from coronary
artery bypass graft surgery (CABG) as compared to medical therapy. The original STICH
trial randomized patients with CAD and EF 35% to CABG or medical therapy. This
study assessed outcomes of STICH patients who had undergone stress testing (radionuclide
[RN] or dobutamine stress echo [DES]) prior to randomization. Of 399 patients enrolled,
219 had a radionuclide test and 205 had a DES. A total of 256 (64%) patients demonstrated
ischemia. There was no difference between patients with vs those without ischemia in all-
cause mortality (hazard ratio: 1.08, 95% confidence interval: 0.77 to 1.50, p  0.66)
cardiovascular mortality or all-cause mortality plus cardiovascular hospitalization. The authors
concluded that in CAD patients with severe LV dysfunction, inducible myocardial ischemia
does not identify patients with worse prognosis or those with greater benefit from CABG
over optimal medical therapy.
Editorial Comment: Raymond J. Gibbons, MD, Todd D. Miller, p. 1871(continued on page A-26)
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HHEART FAILURE1874Pulsatile Hemodynamics and HFPEFThomas Weber, Siegfried Wassertheurer, Michael F. O’Rourke, Anton Haiden, Robert Zweiker,
Martin Rammer, Bernhard Hametner, Bernd Eber
In this trial, Weber and colleagues evaluate whether simple brachial pulse pressure (BPP) or
more precise measures of pulsatile arterial function can be used to diagnosis heart failure with
preserved ejection fraction (HFPEF) in patients with dyspnea on exertion and preserved
systolic function. Patients with major symptoms of dyspnea on exertion and normal ejection
fraction undergoing cardiac catheterization were prospectively enrolled. Patients were
categorized as HFPEF (left ventricular end-diastolic pressure [LVEDP] 16 mm Hg and
N-terminal pro–B-type natriuretic peptide 220 pg/ml, no heart failure with preserved
jection fraction, LVEDP 12 mm Hg and NT-pro-BNP 120 pg/ml, or possible
FPEF. All patients underwent tissue Doppler echocardiography (TDE) and arterial
ulsatile function invasively and noninvasively. Receiver-operating curve analysis derived area
nder the curve (AUC) value for separating HFPEF from no HFPEF was 0.823 for TDE.
dding various measure of pulsatile function to the TDE resulted in an increase in AUC and
net reclassification improvement of 32.9% (p  0.0001). The authors concluded that
easures of pulsatile arterial hemodynamics may complement TDE for the diagnosis of
FPEF.HEART FAILURE1884Heme and Heart FailureArineh Khechaduri, Marina Bayeva, Hsiang-Chun Chang, Hossein Ardehali
Mitochondria dysfunction is common in hypertrophied and failing hearts. Mitochondria play
a major role in regulation of iron balance and synthesis of heme and iron sulfur (Fe/S)
clusters. The goal of this study was to characterize the regulation of heme and non-heme iron
in human failing heart. Mitochondria and cytosolic heme and non-heme iron levels were
measured in failing human hearts retrieved during cardiac transplant surgery. In addition,
genes regulating cellular iron hemostasis, heme biosynthetic pathway, and microRNA that
target iron regulatory networks were examined. The results demonstrate both cytosolic and
mitochondria heme levels were increased in failing heart with feedback inhibition of the heme
synthetic enzyme except for ALA synthase 2 (ALAS 2). Also studied and seen in H9c2
cardiac myoblasts was that ALAS 2 was overexpressed resulting in increased heme levels.
Increased heme levels in cardiac myoblast were associated with excessive production of
reactive oxygen species and cell death. The authors conclude that despite global mitochondrial
dysfunction, heme levels are maintained above baseline in human failing hearts and may
represent a important pathophysiological finding in heart failure.(continued on page A-27)
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EHEART RHYTHM DISORDERS1894Ablation Versus Rate-Control for AF in HFDavid G. Jones, Shouvik K. Haldar, Wajid Hussain, Rakesh Sharma, Darrel P. Francis,
Shelley L. Rahman-Haley, Theresa A. McDonagh, S. Richard Underwood, Vias Markides, Tom Wong
Optimal therapy for atrial fibrillation (AF) in heart failure (HF) is unclear. Jones and
colleagues evaluate catheter ablation vs rate control for HF patients with persistent AF.
Patients with symptomatic HF, radionuclide left ventricular ejection fraction (EF) 35%, and
persistent AF were randomized to undergo catheter ablation or rate control. Primary outcome
was a 12-month change in peak oxygen consumption (VO2). Secondary outcomes included
uality of life and BNP. Fifty two patients were randomized (26 ablation). Eighty eight
ercent of the ablation patients maintained sinus rhythm at 12 months. Peak VO2
significantly increased in the ablation arm (difference 3.07 ml/kg/min, 95% confidence
nterval: 0.56 to 5.59, p  0.018). Ablation improved Minnesota score (p  0.018) and BNP
p  0.045). This randomized trial showed significant benefit from ablation in objective
xercise performance, symptoms and neurohormonal status in patients with AF and HF.ditorial Comment: Mark D. O’Neill, p. 1904BIOMARKERS1906Cardiac Troponin in Subjects From the CommunityKai M. Eggers, Per Venge, Bertil Lindahl, Lars Lind
By using high-sensitive assays, elevated levels of troponin may be detected in the general
population. Elevated levels are usually associated with chronic cardiac conditions of left
ventricular hypertrophy, depressed systolic function, and myocardial ischemia in stable
coronary artery disease patients. To further investigate this phenomena, cardiac troponin I
(cTnI) was measured using a high-sensitive assay in a community-based cohort of 70 year
olds from the study. CTnI was measured in 1,004 individuals and second level was measured
5 years later. Detectable levels of CTnI were found in 96% of participants at baseline and
99% at 5-year follow up. Elevated levels were associated with both all-cause mortality and
cardiovascular mortality. Eggers and colleagues conclude that using high sensitive assay, cTnI
levels are elevated in nearly all elderly subjects studied, increased over time and were strong
markers of mortality risk. This may provide potential for evaluating primary prevention
strategies.
Editorial Comment: Lori B. Daniels, p. 1914(continued on page A-28)
MAY 7, 2013 (continued) A-28VASCULAR DISEASE1917Stent Grafting for Ascending Aortic DissectionQingsheng Lu, Jiaxuan Feng, Jian Zhou, Zhiqing Zhao, Junmin Bao, Rui Feng, Liangxi Yuan, Xiang Feng,
Lefeng Qu, Yifei Pei, Zhijun Mei, Zaiping Jing
Lu and colleagues report on the outcome of treating ascending aortic dissections with
endovascular repair in patients ineligible for traditional direct surgical repair. Fifteen of 41
consecutive patients with aortic dissection referred underwent endovascular repair. Median
time from dissection to treatment was 25.5 days (range 6 to 353 days). Stent graft were
deployed successfully in all. There was no mortality during the perioperative period or at a
median follow up of 26 months (range 16 to 35 months). Significant enlargement of the true
lumen and decrease of the false lumen and thoracic aorta was noted. The authors conclude
that endovascular repair of ascending aortic dissections was appropriate in patients deemed
poor surgical candidates, however, further larger and long-term studies are needed.
